Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for depressive symptoms in breast cancer surgery patients
ChiCTR2400090873Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and breast cancer comparing Esketamine group with Placebo group (2 arms). Primary endpoint: Incidence of moderate to severe depression on postoperative day 1. Started Dec 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)breast cancer
Beyond the preview
Go deeper on ChiCTR2400090873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090873.